Committee to seek more testimony on prosthetics coverage, to hear bill on specialty medications for rare diseases

Unidentified Speaker 1 raised the topic of expanding coverage for multiple prosthetics and asked whether the committee wanted further testimony. "We would obviously need to hear from our insurers, as it would affect benefit plans," Speaker 1 said, and also suggested the Department of Vermont Health Access be invited for Medicaid impact analysis.

Members noted the initial testimony had been focused on athletes and pressed to hear from non-athlete patients and insurers to understand broader cost and equity implications. "I'd be interested in hearing about people who are not athletes, how this would affect them," Unidentified Speaker 5 said.

Representative Boswell's bill (number cited as 736) on specialty medications for rare diseases was also flagged for Friday testimony; Speaker 5 noted the national Rare Disease Day on Feb. 19 and that national organizations might provide useful testimony. Members said they would coordinate scheduling so testimony could be shared or referred where appropriate.

Why it matters: expanding prosthetics coverage or changing pharmacy coverage for specialty drugs affects insurers, Medicaid budgets and patients who rely on costly treatments; committee members emphasized hearing payer, patient and DVHA perspectives before taking action.

Next steps: Staff to identify and invite insurer representatives, DVHA officials and patient advocates; the committee will take testimony on Bill 736 and related prosthetics testimony in forthcoming sessions.